Liraglutide CAS 204656-20-2 API

 

Liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist, produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae, has been engineered to be 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34. Liraglutide is originated from attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. The molecular formula of liraglutide is C172H265N43O51 and the molecular weight is 3751.2 Daltons.

 

 

Chemical Name	Liraglutide
CAS NO.	204656-20-2
Appearance	White powder or crystalline
Molecular Formula	C172H265N43O51
Molecular Weight	3751.2
Purity by Genohope	99% min
Annual Capacity by Genohope	50kg/year
Process by Genohope	Semi-Fermented & Semi-Synthesis
Molecular Structure

 

 

Liraglutide, sold under the brand names Victoza and Saxenda, is an antidiabetic subcutaneous drug used to treat type 2 diabetes and chronic obesity.

Liraglutide was approved for medical use in the European Union in 2009 and in the United States in 2010.

In 2020, it was the 146th most commonly prescribed drug in the United States, with more than 4 million prescriptions filled.

 

 

Liraglutide, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia) .

 

 

Liraglutide is an acylated human Glucagon-Like Peptide-1 (GLP-1) receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). GLP-1(7-37) represents <20% of total circulating endogenous GLP-1. Like GLP-1(7-37), liraglutide activates the GLP-1 receptor, a membrane[1]bound cell-surface receptor coupled to adenylyl cyclase by the stimulatory G-protein, Gs, in pancreatic beta cells. Liraglutide increases intracellular cyclic AMP (cAMP) leading to insulin release in the presence of elevated glucose concentrations. This insulin secretion subsides as blood glucose concentrations decrease and approach euglycemia. Liraglutide also decreases glucagon secretion in a glucose-dependent manner. The mechanism of blood glucose lowering also involves a delay in gastric emptying.

 

GLP-1(7-37) has a half-life of 1.5-2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidases (NEP). Unlike native GLP-1, liraglutide is stable against metabolic degradation by both peptidases and has a plasma half-life of 13 hours after subcutaneous administration. The pharmacokinetic profile of liraglutide, which makes it suitable for once daily administration, is a result of self-association that delays absorption, plasma protein binding and stability against metabolic degradation by DPP-IV and NEP.

 

http://www.genohopebio.com/